LivaNova PLC
$ 80.78
2.80%
12 Aug - close price
- Market Cap 4,316,677,000 USD
- Current Price $ 80.78
- High / Low $ 81.56 / 76.72
- Stock P/E 22.58
- Book Value 24.07
- EPS 3.48
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.15 %
- 52 Week High 85.76
- 52 Week Low 48.82
About
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$89.40
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-25 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 |
| Reported EPS | 1.02 | 0.98 | 0.86 | 0.97 | 1.05 | 0.88 | 0.81 | 0.9 | 0.93 | 0.73 | 0.87 | 0.73 |
| Estimated EPS | 0.96 | 0.9 | 0.8104 | 0.78 | 0.87 | 0.76 | 0.8006 | 0.72 | 0.78 | 0.49 | 0.77 | 0.64 |
| Surprise | 0.06 | 0.08 | 0.0496 | 0.19 | 0.18 | 0.12 | 0.0094 | 0.18 | 0.15 | 0.24 | 0.1 | 0.09 |
| Surprise Percentage | 6.25% | 8.8889% | 6.1204% | 24.359% | 20.6897% | 15.7895% | 1.1741% | 25% | 19.2308% | 48.9796% | 12.987% | 14.0625% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LIVN
2026-08-12 00:00:36
LivaNova PLC has reported a planned sale of 2,675 shares of common stock, stemming from the exercise of employee stock appreciation rights. The transaction, valued at $209,942.40, is scheduled for August 11, 2026, and will be executed through Merrill Lynch as a broker-assisted cashless exercise on NASDAQ. This Form 144 filing provides transparency regarding the upcoming sale of employee-held shares.
2026-08-11 16:48:00
This article provides a price-driven insight into Livanova Plc (NASDAQ: LIVN) for rule-based trading strategies. It highlights weak near-term sentiment challenging long-term strength, with support being tested. The analysis identifies an exceptional 28.8:1 risk-reward setup targeting an 8.4% gain against 0.3% risk, and outlines institutional trading strategies (Position, Momentum Breakout, Risk Hedging) based on AI models across different time horizons.
2026-08-11 00:41:36
LivaNova (LIVN) reported a significant turnaround in Q2 2026, swinging back to profitability with US$108.57 million in net income and US$390.59 million in sales. This performance, along with the recent PMA approval of its aura6000 system for obstructive sleep apnea, strengthens its investment narrative, though risks like pricing pressure and R&D spending persist. Despite the positive earnings, the stock was down 7.6%, prompting an exploration of how these results reshape its financial outlook.
2026-08-10 17:40:10
LivaNova (LIVN) reported a significant turnaround in Q2 2026, swinging back to profitability with US$108.57 million in net income and US$390.59 million in sales. This improvement was driven by strong first-half sales of US$752.85 million and a shift from a prior-year loss, strengthening the company's investment narrative. The company's recent PMA approval for the aura6000 system for obstructive sleep apnea is expected to diversify its revenue streams, though potential challenges like pricing pressure and R&D costs remain.
2026-08-09 07:43:19
This article provides a brief overview of LivaNova Plc's forward price-to-earnings ratio on the Frankfurt Stock Exchange (FWB:LIA). It highlights that the market is currently closed with no trades, and the content is primarily focused on the financial data of the company. The page also offers various tools and resources available on the TradingView platform.
2026-08-06 18:09:50
LivaNova PLC (LIVN) reported record revenue of $391 million and adjusted EPS of $1.26 for Q2 2026, driven by strong growth in both Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted EPS guidance to $4.30-$4.40, reflecting robust operational performance. Despite these positive results, the company lowered its free cash flow guidance due to increased capital spending and an OSA program timeline delay.
